表紙:細胞遺伝学市場の2030年までの予測:製品別、技術別、用途別、エンドユーザー別、地域別の世界分析
市場調査レポート
商品コード
1372035

細胞遺伝学市場の2030年までの予測:製品別、技術別、用途別、エンドユーザー別、地域別の世界分析

Cytogenetics Market Forecasts to 2030 - Global Analysis By Product, Technique, Application, End User and By Geography


出版日
ページ情報
英文 200+ Pages
納期
2~3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.76円
細胞遺伝学市場の2030年までの予測:製品別、技術別、用途別、エンドユーザー別、地域別の世界分析
出版日: 2023年10月01日
発行: Stratistics Market Research Consulting
ページ情報: 英文 200+ Pages
納期: 2~3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

Stratistics MRCによると、世界の細胞遺伝学市場は2023年に27億米ドルを占め、予測期間中にCAGR 11.8%で成長し、2030年には61億米ドルに達すると予測されています。

生物の遺伝的構成における染色体、遺伝子、およびそれらの構造的・数値的変異の研究は、細胞遺伝学の広範なカテゴリーに属し、幅広い方法、機器、サービスを含みます。細胞遺伝学は、遺伝的異常の発見、遺伝的疾患の検出、がんのような疾患の遺伝的背景の理解に役立つ、極めて重要な分野です。その応用分野は臨床診断、調査、個別化医療です。

WHOによると、2018年には約1,810万人が新たにがんと診断され、960万人ががんで死亡しています。

細胞遺伝学に対する高い需要

細胞遺伝学需要の増加には数多くの理由があります。まず第一に、がん、出生時の奇形、遺伝性疾患を理解するのに不可欠です。さらに、精密医療がますます普及するにつれて、遺伝子診断と個別化された治療計画がますます重要になってきています。さらに、健康や病気に対する遺伝的関与の理解拡大や高齢化により、臨床、調査、診断用途における細胞遺伝学検査の需要は増加の一途をたどっています。したがって、ヒトゲノムと疾患の遺伝学に関する研究の拡大が需要を増大させています。

高コスト

細胞遺伝学的検査には、専門的な道具、消耗品、訓練を受けた作業員の使用が必要であり、そのすべてに費用がかかります。患者はしばしばこれらの費用を請求され、遺伝学的診断やカウンセリングを受ける能力を制限されます。また、病院や研究施設にとっては、経済的な困難が生じることもあります。新しい細胞遺伝学的技術の創造と使用もまた、高コストによって妨げられています。したがって、これらの側面が市場の成長を妨げています。

がん治療における新たなイノベーション

がんの発生率が上昇するにつれ、数多くの分子細胞遺伝学的技術ががんの診断に頻繁に使用されるようになっています。加えて、染色体レベルでのがんについての理解が深まるにつれ、細胞遺伝学の収益が拡大しており、これはがん研究の成長によって後押しされています。例えば、この市場の開拓は、がんに関連する遺伝子マーカーに関する重要な情報を提供するFISHやCGH手技の使用によって促進されています。FISH、染色体画像解析、フローソーティング、ゲノムin-situハイブリダイゼーション(GISH)は、合成植物染色体の作成に使用される方法で、遺伝地図、物理地図、分子地図、比較地図の作成に採用されています。さらに、作物改良における分子細胞遺伝学の応用分野の拡大と利点が、市場の成長を支えています。

不利な報酬

不利な報酬慣行は細胞遺伝学業界にとって有害です。ヘルスケアプロバイダーは、一貫性のない、あるいは不十分な支払いの結果、細胞遺伝学的検査や治療を行う可能性が低くなり、患者のアクセスが制限されます。さらに、これは需要を減少させ、研究開発の経済的インセンティブを低下させることにより、市場に影響を与えます。さらに、最先端の細胞遺伝学的検査へのアクセスをめぐって意見が対立し、患者ががんや遺伝性疾患などの疾患に対する重要な遺伝子診断を受けられなくなる可能性もあります。そのため、市場拡大の大きな妨げとなっています。

COVID-19の影響

細胞遺伝学市場はCOVID-19の大流行によってマイナスの影響を受けた。封鎖と資源の再配分により、研究所の業務に支障をきたし、遺伝子検査の遅延と患者アクセスの問題を引き起こしました。さらに、経済の不確実性により、研究・検査プロジェクトの資金が制限され、サプライチェーンの中断により、必要な検査用品へのアクセスが妨げられました。さらに、学術的・臨床的な研究活動も阻害され、臨床的・科学的な後退を招いた。したがって、これらの要因は市場の成長を著しく阻害しました。

予測期間中、核型検査分野が最大となる見込み

カリオタイピングセグメントが最大のシェアを占めると推定されます。通常、血液または組織サンプルから、人の染色体全体を可視化し検査します。さらに、カリオタイピングは染色体構造や数値異常の検出を補助し、がん、遺伝性疾患、出生前検査の診断に役立ちます。さらに、スペクトル核型検査や蛍光in situハイブリダイゼーション(FISH)のようなより高度な技術は、より高い解像度を提供しますが、従来の核型検査の手順には染色体の染色と顕微鏡検査が含まれます。従って、染色体異常や遺伝病に関する貴重な洞察により、核型分析は臨床および研究細胞遺伝学の要であり続けています。

個別化医療セグメントは予測期間中最も高いCAGRが見込まれる

個別化医療分野は、患者の遺伝子プロファイルに医療を適応させる分野が急速に拡大しているため、予測期間中にCAGRが最も高くなると予想されます。臨床医は、染色体分析や分子検査などの細胞遺伝学的手順を利用することで、薬物療法への反応、病気へのかかりやすさ、一般的な健康状態に影響する遺伝的差異を見つけることができます。さらに、この方法によって、より正確な診断と治療の選択が可能になり、治療結果が改善され、悪影響が軽減されます。さらに、ゲノミクスと細胞遺伝学技術の向上により、個別化医療は珍しい病気、薬理ゲノミクス、がんの同定において重要な役割を果たしており、患者の遺伝子プロファイルに基づいて個別化された標的治療計画を提供することで医療に革命をもたらしています。したがって、市場規模の拡大に役立っています。

最大のシェアを占める地域

アジア太平洋地域は、資金提供や協力的な取り組みを通じて、世界中の政府や学術機関が遺伝子研究や診断を積極的に奨励しているため、推定期間中に最大の市場シェアを獲得しました。例えば、インドの"Genome India Project"は、インドゲノムの網羅的な地図を作成しようとしています。さらに、中国や日本のような国々は、遺伝子診断やオーダーメイド医療を進歩させるためにゲノミクスの取り組みを開始しています。さらに、アジア太平洋地域は、大規模で多様な人口に支えられたこれらのプログラムにより、遺伝子研究、イノベーション、臨床応用の焦点となりつつあります。

CAGRが最も高い地域:

北米は、有名な研究機関、バイオテクノロジー企業、医療施設がこの地域にあり、細胞遺伝学の革新と研究を支えているため、予測期間中に有益な成長が見られると予想されます。さらに、強固なヘルスケアシステムと積極的な政府政策により、細胞遺伝学的検査を臨床に取り入れることが容易になり、個別化医療と精密医療が促進されています。さらに、この地域は、北米の細胞遺伝学におけるリーダーシップと強力な規制環境により、遺伝子診断と研究の最前線にあり、市場の成長と進歩を促進しています。

無料のカスタマイズサービス

本レポートをご購読のお客様には、以下の無料カスタマイズオプションのいずれかをご利用いただけます:

  • 企業プロファイル
    • 追加市場プレイヤーの包括的プロファイリング(3社まで)
    • 主要企業のSWOT分析(3社まで)
  • 地域セグメンテーション
    • 顧客の関心に応じた主要国の市場推計・予測・CAGR(注:フィージビリティチェックによる)
  • 競合ベンチマーキング
    • 製品ポートフォリオ、地理的プレゼンス、戦略的提携に基づく主要企業のベンチマーキング

目次

第1章 エグゼクティブサマリー

第2章 序文

  • 概要
  • ステークホルダー
  • 調査範囲
  • 調査手法
    • データマイニング
    • データ分析
    • データ検証
    • 調査アプローチ
  • 調査ソース
    • 1次調査ソース
    • 2次調査ソース
    • 前提条件

第3章 市場動向分析

  • 促進要因
  • 抑制要因
  • 機会
  • 脅威
  • 製品分析
  • アプリケーション分析
  • エンドユーザー分析
  • 新興市場
  • 新型コロナウイルス感染症(COVID-19)の影響

第4章 ポーターのファイブフォース分析

  • 供給企業の交渉力
  • 買い手の交渉力
  • 代替品の脅威
  • 新規参入業者の脅威
  • 競争企業間の敵対関係

第5章 世界の細胞遺伝学市場:製品別

  • 消耗品
    • 検査キット、培地、および試薬
    • プローブ
    • アフィニティー試薬と染色剤
    • その他の消耗品
  • 楽器
  • ソフトウェアとサービス
  • その他の製品

第6章 世界の細胞遺伝学市場:技術別

  • 比較ゲノムハイブリダイゼーション
  • 蛍光In situハイブリダイゼーション
  • 核型分析
  • 免疫組織化学
  • その他のテクニック

第7章 世界の細胞遺伝学市場:アプリケーション別

  • 遺伝性疾患
  • がん
  • 個別化医療
  • その他の用途

第8章 世界の細胞遺伝学市場:エンドユーザー別

  • 臨床調査室
  • 製薬およびバイオテクノロジー企業
  • 学術調査
  • その他のエンドユーザー

第9章 世界の細胞遺伝学市場:地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • イタリア
    • フランス
    • スペイン
    • その他欧州
  • アジア太平洋地域
    • 日本
    • 中国
    • インド
    • オーストラリア
    • ニュージーランド
    • 韓国
    • その他アジア太平洋地域
  • 南米
    • アルゼンチン
    • ブラジル
    • チリ
    • その他南米
  • 中東とアフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • カタール
    • 南アフリカ
    • その他中東とアフリカ

第10章 主な発展

  • 契約、パートナーシップ、コラボレーション、合弁事業
  • 買収と合併
  • 新製品の発売
  • 事業拡大
  • その他の主要戦略

第11章 企業プロファイル

  • Thermo Fisher Scientific, Inc.
  • Sysmex Corporation
  • PerkinElmer, Inc.
  • OPKO Health, Inc.
  • Irvine Scientific
  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • Applied Spectrial Imaging, Inc.
  • Empire Genomics, LLC
図表

List of Tables

  • Table 1 Global Cytogenetics Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Cytogenetics Market Outlook, By Product (2021-2030) ($MN)
  • Table 3 Global Cytogenetics Market Outlook, By Consumable (2021-2030) ($MN)
  • Table 4 Global Cytogenetics Market Outlook, By Testing Kits, Media, and Reagents (2021-2030) ($MN)
  • Table 5 Global Cytogenetics Market Outlook, By Probes (2021-2030) ($MN)
  • Table 6 Global Cytogenetics Market Outlook, By Affinity Reagents and Stains (2021-2030) ($MN)
  • Table 7 Global Cytogenetics Market Outlook, By Other Consumables (2021-2030) ($MN)
  • Table 8 Global Cytogenetics Market Outlook, By Instrument (2021-2030) ($MN)
  • Table 9 Global Cytogenetics Market Outlook, By Software & Service (2021-2030) ($MN)
  • Table 10 Global Cytogenetics Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 11 Global Cytogenetics Market Outlook, By Technique (2021-2030) ($MN)
  • Table 12 Global Cytogenetics Market Outlook, By Comparitive Genome Hybridization (2021-2030) ($MN)
  • Table 13 Global Cytogenetics Market Outlook, By Fluorescence In Situ Hybridization (2021-2030) ($MN)
  • Table 14 Global Cytogenetics Market Outlook, By Karyotyping (2021-2030) ($MN)
  • Table 15 Global Cytogenetics Market Outlook, By Immunohistochemistry (2021-2030) ($MN)
  • Table 16 Global Cytogenetics Market Outlook, By Other Techniques (2021-2030) ($MN)
  • Table 17 Global Cytogenetics Market Outlook, By Application (2021-2030) ($MN)
  • Table 18 Global Cytogenetics Market Outlook, By Genetic Disorder (2021-2030) ($MN)
  • Table 19 Global Cytogenetics Market Outlook, By Cancer (2021-2030) ($MN)
  • Table 20 Global Cytogenetics Market Outlook, By Personalized Medicine (2021-2030) ($MN)
  • Table 21 Global Cytogenetics Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 22 Global Cytogenetics Market Outlook, By End User (2021-2030) ($MN)
  • Table 23 Global Cytogenetics Market Outlook, By Clinical and Research Laboratory (2021-2030) ($MN)
  • Table 24 Global Cytogenetics Market Outlook, By Pharmaceutical and Biotechnology Company (2021-2030) ($MN)
  • Table 25 Global Cytogenetics Market Outlook, By Academic Research Institute (2021-2030) ($MN)
  • Table 26 Global Cytogenetics Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 27 North America Cytogenetics Market Outlook, By Country (2021-2030) ($MN)
  • Table 28 North America Cytogenetics Market Outlook, By Product (2021-2030) ($MN)
  • Table 29 North America Cytogenetics Market Outlook, By Consumable (2021-2030) ($MN)
  • Table 30 North America Cytogenetics Market Outlook, By Testing Kits, Media, and Reagents (2021-2030) ($MN)
  • Table 31 North America Cytogenetics Market Outlook, By Probes (2021-2030) ($MN)
  • Table 32 North America Cytogenetics Market Outlook, By Affinity Reagents and Stains (2021-2030) ($MN)
  • Table 33 North America Cytogenetics Market Outlook, By Other Consumables (2021-2030) ($MN)
  • Table 34 North America Cytogenetics Market Outlook, By Instrument (2021-2030) ($MN)
  • Table 35 North America Cytogenetics Market Outlook, By Software & Service (2021-2030) ($MN)
  • Table 36 North America Cytogenetics Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 37 North America Cytogenetics Market Outlook, By Technique (2021-2030) ($MN)
  • Table 38 North America Cytogenetics Market Outlook, By Comparitive Genome Hybridization (2021-2030) ($MN)
  • Table 39 North America Cytogenetics Market Outlook, By Fluorescence In Situ Hybridization (2021-2030) ($MN)
  • Table 40 North America Cytogenetics Market Outlook, By Karyotyping (2021-2030) ($MN)
  • Table 41 North America Cytogenetics Market Outlook, By Immunohistochemistry (2021-2030) ($MN)
  • Table 42 North America Cytogenetics Market Outlook, By Other Techniques (2021-2030) ($MN)
  • Table 43 North America Cytogenetics Market Outlook, By Application (2021-2030) ($MN)
  • Table 44 North America Cytogenetics Market Outlook, By Genetic Disorder (2021-2030) ($MN)
  • Table 45 North America Cytogenetics Market Outlook, By Cancer (2021-2030) ($MN)
  • Table 46 North America Cytogenetics Market Outlook, By Personalized Medicine (2021-2030) ($MN)
  • Table 47 North America Cytogenetics Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 48 North America Cytogenetics Market Outlook, By End User (2021-2030) ($MN)
  • Table 49 North America Cytogenetics Market Outlook, By Clinical and Research Laboratory (2021-2030) ($MN)
  • Table 50 North America Cytogenetics Market Outlook, By Pharmaceutical and Biotechnology Company (2021-2030) ($MN)
  • Table 51 North America Cytogenetics Market Outlook, By Academic Research Institute (2021-2030) ($MN)
  • Table 52 North America Cytogenetics Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 53 Europe Cytogenetics Market Outlook, By Country (2021-2030) ($MN)
  • Table 54 Europe Cytogenetics Market Outlook, By Product (2021-2030) ($MN)
  • Table 55 Europe Cytogenetics Market Outlook, By Consumable (2021-2030) ($MN)
  • Table 56 Europe Cytogenetics Market Outlook, By Testing Kits, Media, and Reagents (2021-2030) ($MN)
  • Table 57 Europe Cytogenetics Market Outlook, By Probes (2021-2030) ($MN)
  • Table 58 Europe Cytogenetics Market Outlook, By Affinity Reagents and Stains (2021-2030) ($MN)
  • Table 59 Europe Cytogenetics Market Outlook, By Other Consumables (2021-2030) ($MN)
  • Table 60 Europe Cytogenetics Market Outlook, By Instrument (2021-2030) ($MN)
  • Table 61 Europe Cytogenetics Market Outlook, By Software & Service (2021-2030) ($MN)
  • Table 62 Europe Cytogenetics Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 63 Europe Cytogenetics Market Outlook, By Technique (2021-2030) ($MN)
  • Table 64 Europe Cytogenetics Market Outlook, By Comparitive Genome Hybridization (2021-2030) ($MN)
  • Table 65 Europe Cytogenetics Market Outlook, By Fluorescence In Situ Hybridization (2021-2030) ($MN)
  • Table 66 Europe Cytogenetics Market Outlook, By Karyotyping (2021-2030) ($MN)
  • Table 67 Europe Cytogenetics Market Outlook, By Immunohistochemistry (2021-2030) ($MN)
  • Table 68 Europe Cytogenetics Market Outlook, By Other Techniques (2021-2030) ($MN)
  • Table 69 Europe Cytogenetics Market Outlook, By Application (2021-2030) ($MN)
  • Table 70 Europe Cytogenetics Market Outlook, By Genetic Disorder (2021-2030) ($MN)
  • Table 71 Europe Cytogenetics Market Outlook, By Cancer (2021-2030) ($MN)
  • Table 72 Europe Cytogenetics Market Outlook, By Personalized Medicine (2021-2030) ($MN)
  • Table 73 Europe Cytogenetics Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 74 Europe Cytogenetics Market Outlook, By End User (2021-2030) ($MN)
  • Table 75 Europe Cytogenetics Market Outlook, By Clinical and Research Laboratory (2021-2030) ($MN)
  • Table 76 Europe Cytogenetics Market Outlook, By Pharmaceutical and Biotechnology Company (2021-2030) ($MN)
  • Table 77 Europe Cytogenetics Market Outlook, By Academic Research Institute (2021-2030) ($MN)
  • Table 78 Europe Cytogenetics Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 79 Asia Pacific Cytogenetics Market Outlook, By Country (2021-2030) ($MN)
  • Table 80 Asia Pacific Cytogenetics Market Outlook, By Product (2021-2030) ($MN)
  • Table 81 Asia Pacific Cytogenetics Market Outlook, By Consumable (2021-2030) ($MN)
  • Table 82 Asia Pacific Cytogenetics Market Outlook, By Testing Kits, Media, and Reagents (2021-2030) ($MN)
  • Table 83 Asia Pacific Cytogenetics Market Outlook, By Probes (2021-2030) ($MN)
  • Table 84 Asia Pacific Cytogenetics Market Outlook, By Affinity Reagents and Stains (2021-2030) ($MN)
  • Table 85 Asia Pacific Cytogenetics Market Outlook, By Other Consumables (2021-2030) ($MN)
  • Table 86 Asia Pacific Cytogenetics Market Outlook, By Instrument (2021-2030) ($MN)
  • Table 87 Asia Pacific Cytogenetics Market Outlook, By Software & Service (2021-2030) ($MN)
  • Table 88 Asia Pacific Cytogenetics Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 89 Asia Pacific Cytogenetics Market Outlook, By Technique (2021-2030) ($MN)
  • Table 90 Asia Pacific Cytogenetics Market Outlook, By Comparitive Genome Hybridization (2021-2030) ($MN)
  • Table 91 Asia Pacific Cytogenetics Market Outlook, By Fluorescence In Situ Hybridization (2021-2030) ($MN)
  • Table 92 Asia Pacific Cytogenetics Market Outlook, By Karyotyping (2021-2030) ($MN)
  • Table 93 Asia Pacific Cytogenetics Market Outlook, By Immunohistochemistry (2021-2030) ($MN)
  • Table 94 Asia Pacific Cytogenetics Market Outlook, By Other Techniques (2021-2030) ($MN)
  • Table 95 Asia Pacific Cytogenetics Market Outlook, By Application (2021-2030) ($MN)
  • Table 96 Asia Pacific Cytogenetics Market Outlook, By Genetic Disorder (2021-2030) ($MN)
  • Table 97 Asia Pacific Cytogenetics Market Outlook, By Cancer (2021-2030) ($MN)
  • Table 98 Asia Pacific Cytogenetics Market Outlook, By Personalized Medicine (2021-2030) ($MN)
  • Table 99 Asia Pacific Cytogenetics Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 100 Asia Pacific Cytogenetics Market Outlook, By End User (2021-2030) ($MN)
  • Table 101 Asia Pacific Cytogenetics Market Outlook, By Clinical and Research Laboratory (2021-2030) ($MN)
  • Table 102 Asia Pacific Cytogenetics Market Outlook, By Pharmaceutical and Biotechnology Company (2021-2030) ($MN)
  • Table 103 Asia Pacific Cytogenetics Market Outlook, By Academic Research Institute (2021-2030) ($MN)
  • Table 104 Asia Pacific Cytogenetics Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 105 South America Cytogenetics Market Outlook, By Country (2021-2030) ($MN)
  • Table 106 South America Cytogenetics Market Outlook, By Product (2021-2030) ($MN)
  • Table 107 South America Cytogenetics Market Outlook, By Consumable (2021-2030) ($MN)
  • Table 108 South America Cytogenetics Market Outlook, By Testing Kits, Media, and Reagents (2021-2030) ($MN)
  • Table 109 South America Cytogenetics Market Outlook, By Probes (2021-2030) ($MN)
  • Table 110 South America Cytogenetics Market Outlook, By Affinity Reagents and Stains (2021-2030) ($MN)
  • Table 111 South America Cytogenetics Market Outlook, By Other Consumables (2021-2030) ($MN)
  • Table 112 South America Cytogenetics Market Outlook, By Instrument (2021-2030) ($MN)
  • Table 113 South America Cytogenetics Market Outlook, By Software & Service (2021-2030) ($MN)
  • Table 114 South America Cytogenetics Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 115 South America Cytogenetics Market Outlook, By Technique (2021-2030) ($MN)
  • Table 116 South America Cytogenetics Market Outlook, By Comparitive Genome Hybridization (2021-2030) ($MN)
  • Table 117 South America Cytogenetics Market Outlook, By Fluorescence In Situ Hybridization (2021-2030) ($MN)
  • Table 118 South America Cytogenetics Market Outlook, By Karyotyping (2021-2030) ($MN)
  • Table 119 South America Cytogenetics Market Outlook, By Immunohistochemistry (2021-2030) ($MN)
  • Table 120 South America Cytogenetics Market Outlook, By Other Techniques (2021-2030) ($MN)
  • Table 121 South America Cytogenetics Market Outlook, By Application (2021-2030) ($MN)
  • Table 122 South America Cytogenetics Market Outlook, By Genetic Disorder (2021-2030) ($MN)
  • Table 123 South America Cytogenetics Market Outlook, By Cancer (2021-2030) ($MN)
  • Table 124 South America Cytogenetics Market Outlook, By Personalized Medicine (2021-2030) ($MN)
  • Table 125 South America Cytogenetics Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 126 South America Cytogenetics Market Outlook, By End User (2021-2030) ($MN)
  • Table 127 South America Cytogenetics Market Outlook, By Clinical and Research Laboratory (2021-2030) ($MN)
  • Table 128 South America Cytogenetics Market Outlook, By Pharmaceutical and Biotechnology Company (2021-2030) ($MN)
  • Table 129 South America Cytogenetics Market Outlook, By Academic Research Institute (2021-2030) ($MN)
  • Table 130 South America Cytogenetics Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 131 Middle East & Africa Cytogenetics Market Outlook, By Country (2021-2030) ($MN)
  • Table 132 Middle East & Africa Cytogenetics Market Outlook, By Product (2021-2030) ($MN)
  • Table 133 Middle East & Africa Cytogenetics Market Outlook, By Consumable (2021-2030) ($MN)
  • Table 134 Middle East & Africa Cytogenetics Market Outlook, By Testing Kits, Media, and Reagents (2021-2030) ($MN)
  • Table 135 Middle East & Africa Cytogenetics Market Outlook, By Probes (2021-2030) ($MN)
  • Table 136 Middle East & Africa Cytogenetics Market Outlook, By Affinity Reagents and Stains (2021-2030) ($MN)
  • Table 137 Middle East & Africa Cytogenetics Market Outlook, By Other Consumables (2021-2030) ($MN)
  • Table 138 Middle East & Africa Cytogenetics Market Outlook, By Instrument (2021-2030) ($MN)
  • Table 139 Middle East & Africa Cytogenetics Market Outlook, By Software & Service (2021-2030) ($MN)
  • Table 140 Middle East & Africa Cytogenetics Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 141 Middle East & Africa Cytogenetics Market Outlook, By Technique (2021-2030) ($MN)
  • Table 142 Middle East & Africa Cytogenetics Market Outlook, By Comparitive Genome Hybridization (2021-2030) ($MN)
  • Table 143 Middle East & Africa Cytogenetics Market Outlook, By Fluorescence In Situ Hybridization (2021-2030) ($MN)
  • Table 144 Middle East & Africa Cytogenetics Market Outlook, By Karyotyping (2021-2030) ($MN)
  • Table 145 Middle East & Africa Cytogenetics Market Outlook, By Immunohistochemistry (2021-2030) ($MN)
  • Table 146 Middle East & Africa Cytogenetics Market Outlook, By Other Techniques (2021-2030) ($MN)
  • Table 147 Middle East & Africa Cytogenetics Market Outlook, By Application (2021-2030) ($MN)
  • Table 148 Middle East & Africa Cytogenetics Market Outlook, By Genetic Disorder (2021-2030) ($MN)
  • Table 149 Middle East & Africa Cytogenetics Market Outlook, By Cancer (2021-2030) ($MN)
  • Table 150 Middle East & Africa Cytogenetics Market Outlook, By Personalized Medicine (2021-2030) ($MN)
  • Table 151 Middle East & Africa Cytogenetics Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 152 Middle East & Africa Cytogenetics Market Outlook, By End User (2021-2030) ($MN)
  • Table 153 Middle East & Africa Cytogenetics Market Outlook, By Clinical and Research Laboratory (2021-2030) ($MN)
  • Table 154 Middle East & Africa Cytogenetics Market Outlook, By Pharmaceutical and Biotechnology Company (2021-2030) ($MN)
  • Table 155 Middle East & Africa Cytogenetics Market Outlook, By Academic Research Institute (2021-2030) ($MN)
  • Table 156 Middle East & Africa Cytogenetics Market Outlook, By Other End Users (2021-2030) ($MN)
目次
Product Code: SMRC24091

According to Stratistics MRC, the Global Cytogenetics Market is accounted for $2.7 billion in 2023 and is expected to reach $6.1 billion by 2030 growing at a CAGR of 11.8% during the forecast period. The study of chromosomes, genes, and their structural and numerical variations within an organism's genetic makeup falls under the broad category of cytogenetics, which includes a wide range of methods, instruments, and services. It helps in locating genetic anomalies, detecting genetic disorders, and comprehending the genetic underpinnings of diseases like cancer, this field is crucial. Its applications are in clinical diagnostics, research, and personalized medicine.

According to WHO, in the year 2018 around 18.1 million new cases were diagnosed and 9.6 million individuals died out of cancer.

Market Dynamics:

Driver:

High demand for cytogenetics

Numerous reasons have contributed to the rise in cytogenetic demand. First of all, it is essential to comprehending cancer, birth deformities, and hereditary diseases. Moreover, genetic diagnosis and individualized treatment plans are becoming more and more important as precision medicine becomes more and more popular, cytogenetic testing is now more widely available, precise, and economical thanks to technological improvements. Furthermore, the demand for cytogenetics in clinical, research, and diagnostic applications keeps rising as a result of expanding understanding of the genetic contributions to health and illness as well as an aging population. Therefore, the expansion of research into the human genome and the genetics of diseases have increased demand.

Restraint:

High cost

Cytogenetic testing necessitates the use of specialized tools, consumables, and trained workers, all of which can be expensive. Patients are frequently charged for these costs, which restricts their ability to get genetic diagnostics and counseling. They can present financial difficulties for hospitals and research facilities. The creation and use of new cytogenetic technologies are also hampered by high costs. Hence, these aspects hinder the market growth.

Opportunity:

New innovations in cancer treatment

Numerous molecular cytogenetics techniques are being employed more frequently for cancer diagnosis as the incidence of the disease rises. In addition, as more is understood about cancer at the chromosomal level, this is causing the cytogenetics revenue to expand, which is being fueled by the growth of cancer research. For instance, the development of the market is facilitated by the use of FISH and CGH procedures, which offer vital information on cancer-related genetic markers. FISH, chromosomal image analysis, flow sorting, and genomic in-situ hybridization (GISH), methods used for the creation of synthetic plant chromosomes, are employed in the creation of genetic, physical, molecular, and comparative maps. Moreover, the rising application field and advantages of molecular cytogenetics in crop improvement are therefore assisting the market's growth.

Threat:

Unfavourable compensation

Unfavourable reimbursement practices have been detrimental to the cytogenetics industry. Healthcare providers are less likely to give cytogenetic testing and treatments as a result of inconsistent or insufficient payment, which restricts patient access. Moreover, in turn, this has an impact on the market by decreasing demand and the financial incentives for R&D. Additionally, it may result in disagreements over access to cutting-edge cytogenetic testing, preventing patients from receiving vital genetic diagnostics for diseases like cancer and genetic disorders. Therefore, it is significantly hindering market expansion.

COVID-19 Impact

The cytogenetics market was negatively impacted by the COVID-19 pandemic. Due to lockdowns and resource redistribution, it interfered with laboratory operations, causing delays in genetic testing and problems with patient access. Furthermore, economic uncertainty limited funding for research and testing projects, while supply chain interruptions hindered the accessibility of necessary testing supplies. Moreover, academic and clinical research operations were impeded, which resulted in clinical and scientific setbacks. Therefore, these factors significantly hampered the market growth.

The karyotyping segment is expected to be the largest during the forecast period

The karyotyping segment is estimated to hold the largest share. It entails the visualization and examination of a person's whole chromosomal set, usually from a blood or tissue sample. Additionally, karyotyping aids in the detection of chromosomal structure and numerical anomalies, which aid in the diagnosis of cancer, genetic diseases, and prenatal testing. Moreover, more sophisticated techniques like spectral karyotyping and fluorescent in situ hybridization (FISH) offer higher resolution, traditional karyotyping procedures include staining and microscopic inspection of chromosomes. Therefore, with the invaluable insights into chromosomal abnormalities and genetic illnesses, karyotyping continues to be a cornerstone in clinical and research cytogenetics.

The personalized medicine segment is expected to have the highest CAGR during the forecast period

The personalized medicine segment is anticipated to have highest CAGR during the forecast period, due to a quickly expanding area that adapts medical care to a patient's genetic profile. Clinicians can find genetic differences that affect a person's response to medication, susceptibility to diseases, and general health by utilizing cytogenetic procedures such as chromosomal analysis and molecular testing. Additionally, this method allows for more exact diagnostic and treatment choices, improving therapeutic results and reducing negative effects. Moreover, with improvements in genomics and cytogenetic technology, personalized medicine is playing a crucial role in the identification of uncommon diseases, pharmacogenomics, and cancers, revolutionizing healthcare by offering patients personalized and targeted treatment plans based on their genetic profiles. Thus, helps in expanding the market size.

Region with largest share:

Asia Pacific commanded the largest market share during the extrapolated period owing to a number of initiatives, through funding and cooperative initiatives, governments and academic institutions from all around the region are actively encouraging genetic research and diagnostics. For instance, the "Genome India Project" in India attempts to produce an exhaustive map of the Indian genome. Moreover, nations like China and Japan have launched genomics efforts to advance genetic diagnoses and tailored medicine. Furthermore, the Asia-Pacific area is becoming a focus point for genetic studies, innovations, and clinical applications due to these programs, which are supported by a sizable and diversified population.

Region with highest CAGR:

North America is expected to witness profitable growth over the projection period, owing to renowned research institutions, biotech firms, and medical facilities are located in the area, which supports cytogenetics innovation and study. Additionally, robust healthcare systems and proactive government policies have made it easier to incorporate cytogenetic testing into clinical practice, promoting personalized and precision medicine. Furthermore, the region is at the forefront of genetic diagnostics and research due to North America's leadership in cytogenetics and a strong regulatory environment, which promotes market growth and advancements.

Key players in the market:

Some of the key players in the Cytogenetics Market include: Thermo Fisher Scientific Inc., Sysmex Corporation, PerkinElmer, Inc., OPKO Health, Inc., Irvine Scientific, Abbott Laboratories, Agilent Technologies, Inc., Applied Spectrial Imaging, Inc. and Empire Genomics, LLC.

Key Developments:

In September 2023, Abbott announced it has completed the acquisition of Bigfoot Biomedical, a leader in developing smart insulin management systems for people with diabetes.

In August 2023, Thermo Fisher Scientific Inc. the world leader in serving science, announced that it has completed the acquisition of CorEvitas, LLC ("CorEvitas"), a leading provider of regulatory-grade, real-world evidence for approved medical treatments and therapies, from Audax Private Equity ("Audax).

In August 2023, Thermo Fisher Scientific, the world leader in serving science, announced the commercial launch of the EXENT® Solution, after receiving IVDR certification*. The EXENT solution is a fully integrated and automated mass spectrometry system designed to transform diagnosis and assessment for patients with monoclonal gammopathies, including multiple myeloma.

Products Covered:

  • Consumable
  • Instrument
  • Software & Service
  • Other Products

Techniques Covered:

  • Comparitive Genome Hybridization
  • Fluorescence In Situ Hybridization
  • Karyotyping
  • Immunohistochemistry
  • Other Techniques

Applications Covered:

  • Genetic Disorder
  • Cancer
  • Personalized Medicine
  • Other Applications

End Users Covered:

  • Clinical and Research Laboratory
  • Pharmaceutical and Biotechnology Company
  • Academic Research Institute
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Cytogenetics Market, By Product

  • 5.1 Introduction
  • 5.2 Consumable
    • 5.2.1 Testing Kits, Media, and Reagents
    • 5.2.2 Probes
    • 5.2.3 Affinity Reagents and Stains
    • 5.2.4 Other Consumables
  • 5.3 Instrument
  • 5.4 Software & Service
  • 5.5 Other Products

6 Global Cytogenetics Market, By Technique

  • 6.1 Introduction
  • 6.2 Comparitive Genome Hybridization
  • 6.3 Fluorescence In Situ Hybridization
  • 6.4 Karyotyping
  • 6.5 Immunohistochemistry
  • 6.6 Other Techniques

7 Global Cytogenetics Market, By Application

  • 7.1 Introduction
  • 7.2 Genetic Disorder
  • 7.3 Cancer
  • 7.4 Personalized Medicine
  • 7.5 Other Applications

8 Global Cytogenetics Market, By End User

  • 8.1 Introduction
  • 8.2 Clinical and Research Laboratory
  • 8.3 Pharmaceutical and Biotechnology Company
  • 8.4 Academic Research Institute
  • 8.5 Other End Users

9 Global Cytogenetics Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Thermo Fisher Scientific, Inc.
  • 11.2 Sysmex Corporation
  • 11.3 PerkinElmer, Inc.
  • 11.4 OPKO Health, Inc.
  • 11.5 Irvine Scientific
  • 11.6 Abbott Laboratories
  • 11.7 Agilent Technologies, Inc.
  • 11.8 Applied Spectrial Imaging, Inc.
  • 11.9 Empire Genomics, LLC